Concord Healthcare Group Co., Ltd (Ticker: 2453 HK) is a Hong Kong-based company operating in the Medical Labs & Testing Services industry. Affiliated with Concord Holdings listed on the New York Stock Exchange, the company specializes in cancer prevention, diagnosis, and treatment, and also offers financial leasing and investment in healthcare-related enterprises. With a presence Chinese cities like Beijing, Shanghai, and Guangzhou, Concord Healthcare Group Co., Ltd provides both offline and online medical services, including precision radiotherapy and Internet medical services.

The company is scheduled to list on the Hong Kong Stock Exchange on January 9, 2024. It plans to offer 39.42 million shares, with an expected price range of HKD 14.10 to HKD 16.40 per share, aiming to raise HKD 646.4913 million (USD 82.77 million). The IPO is managed by a consortium of underwriters including ABCI Capital Ltd, CCB International Capital Ltd, CLSA Ltd, CMB International Capital Corp Ltd, China Everbright Securities (HK), and Fosun.